Tirzepatide: A "Twincretin" GameChanger?

Curious about tirzepatide and what it means for patients? Tirzepatide, a combination GLP-1 and GIP agonist, was just approved by the Food and Drug Administration for the treatment of diabetes. Tirzepatide has also gained attention for its weight-reducing effects. However, how does tirzepatide compare to other GLP-1 agonists? Is tirzepaide a GameChanger for type 2 diabetes management? Learn more with host, Geoff Wall.  The GameChanger Tirzepatide is the first in its class to hit the market and has been shown to be as or more effective than semaglutide in glycemic control and weight reduction.   Show Segments 00:00 – Introductions 01:15 – Type 2 Diabetes & Treatment 02:29 – Glucagon-like peptide-1 (GLP-1) Agonists 03:04 – Glucose-dependent insulinotropic polypeptide (GIP) Agonist   03:55 – Tirzepatide vs Semaglutide 14:27 -  Tirzepatide vs Insulin 21:15 – Retinopathy & Financial Considerations 22:30 – Closing Remarks  HostGeoff Wall, PharmD., BCPS, FCCP, CGP Professor of Pharmacy Practice, Drake University Internal Medicine/Critical Care, UnityPoint Health References and Resources Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes Once-Weekly Tirzeaptide Versus Once-Daily Insulin Degludec as Add-On to Metformin With or Without SGLT2 Inhibitors in Patients With Type 2 Diabetes (SURPASS-3): A Randomized, Open-Label, Parallel-Group, Phase 3 Trial  Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients With Type 2 Diabetes (SURPASS-1): A Double-Blind, Randomised, Phase 3 Trial Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial Redeem your CPE or CME here CPE (Pharmacist)  CME (Physician)  Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode) Pharmacists: Get a membership Prescribers: Get a membership CE Information Learning Objectives Upon successful completion of this knowledge-based activity, participants should be able to: Describe the safety and efficacy of tirzepatide compared to GLP-1 agonists Discuss the use of tirzepatide compared to basal insulin for blood glucose control Select a patient who may be a candidate for tirzepatide therapy 0.05 CEU/0.5 HrUAN: 0107-0000-22-234-H01-P Initial release date: 06/27/2022 Expiration date: 06/27/2023 Additional CPE and CME details can be found here. Follow CEimpact on Social Media:LinkedInInstagram